TP与MVP方案治疗晚期非小细胞肺癌疗效比较

目的观察比较泰素加顺铂与丝裂霉素加顺铂及西艾克治疗晚期非小细胞肺癌的近期疗效及不良反应。方法58例晚期非小细胞肺癌患者随机分为Taxol DDP组(A组)及MMC VDS DDP组(B组),治疗2个周期后进行疗效及不良反应评估。结果A组30例,有效率46.7%;B组28例,有效率42.9%。A组的骨髓抑制与周围神经炎较B组为轻。结论TP与MVP方案在治疗晚期非小细胞肺癌方面均有较好疗效,但TP方案不良反应较轻,可作为首选方案。

Results of ComParing TP Regimen with MVP Regimen in Treatment of Advanced Non-small Cell Lung Cancer

Objective To evalute and comPare the efficacy and toxicity of TP and MVP on the treatment of advanced non-small cell lung cancer. Methods Fifty-eight Patients with advanced non-small cell lung cancer were randomized into TP grouP (grouP A) and MVP grouP (grouP B). Efficacies and toxicities were assessed after 2 cycles of treatment for individual Patient. Results The resPonse rate in 30 Patients of grouP A was 46.7% and in Patients of grouP B was 42.9%. MyelosuPPression and PeriPheral neuritis of TP regimen were less serious than these of MVP regimen. Conclusion Both TP and MVP are effective for treatment of advanced non-small cell lung cancer.TP regimen has few side-effects and shall be used as the first-line regimen .